VRX-496(VIRxSYS).
VIRxSYS is developing VRX-496, a lentiviral HIV-based vector encoding anti-HIV antisense envelope sequences, as a potential gene therapy for HIV infection. In July 2003, VIRxSYS undertook the initial dosing of an HIV-positive patient in a phase I/IIa trial.
Morris
Kevin V
KV
Division of Molecular Medicine, Beckman Research Institute at the City of Hope, 1450 East Duarte Road, Duarte, CA 91010-3011, USA. kmorris@coh.org
D016915:AIDS Vaccines / Q000009:adverse effects / Q000138:chemical synthesis / Q000494:pharmacology*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000075202:Contraindications; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D013329:Structure-Activity Relationship
D016915:AIDS Vaccines